The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4+ T lymphocytes

American Journal of Pathology

Volumn 183, Issue 6, 2013, Pages 1971-1980

  Zhang, Qian ^a   Wei, Fang ^a   Wang, Hong Yi ^a   Liu, Xiaobin ^a   Roy, Darshan ^a   Xiong, Qun Bin ^a   Jiang, Shuguang ^a   Medvec, Andrew ^a   Danet Desnoyers, Gwenn ^a   Watt, Christopher ^a   Tomczak, Ewa ^a   Kalos, Michael ^a   Riley, James L ^a   Wasik, Mariusz A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; LARGE CELL LYMPHOMA; MOUSE; NONHUMAN; NPM ALK ONCOGENE; ONCOGENE; PRIORITY JOURNAL;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MICE; ONCOGENE PROTEINS, FUSION; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84888266332     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.08.030     Document Type: Article

References (29)

1. R. Li, and S.W. Morris Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy Med Res Rev 28 2008 372 412
2. M.A. Wasik, Q. Zhang, M. Marzec, M. Kasprzycka, H.Y. Wang, and X. Liu Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches Semin Oncol 36 2 Suppl 1 2009 S27 S35
3. F. Tabbó, A. Barreca, R. Piva, G. Inghirami European T-Cell Lymphoma Study Group ALK signaling and target therapy in anaplastic large cell lymphoma Front Oncol 2 2012 41
4. S.W. Morris, M.N. Kirstein, M.B. Valentine, K.G. Dittmer, D.N. Shapiro, D.L. Saltman, and A.T. Look Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma [Erratum appeared in Science 1995, 267:316-317] Science 263 1994 1281 1284
5. M. Shiota, J. Fujimoto, T. Semba, H. Satoh, T. Yamamoto, and S. Mori Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3 Oncogene 9 1994 1567 1574
6. J. Fujimoto, M. Shiota, T. Iwahara, N. Seki, H. Satoh, S. Mori, and T. Yamamoto Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5) Proc Natl Acad Sci USA 93 1996 4181 4186
7. M.U. Kuefer, A.T. Look, K. Pulford, F.G. Behm, P.K. Pattengale, D.Y. Mason, and S.W. Morris Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice Blood 90 1997 2901 2910
8. R. Chiarle, J.Z. Gong, I. Guasparri, A. Pesci, J. Cai, J. Liu, W.J. Simmons, G. Dhall, J. Howes, R. Piva, and G. Inghirami NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors Blood 101 2003 1919 1927
9. S.D. Turner, H. Merz, D. Yeung, and D.R. Alexander CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy Anticancer Res 26 2006 3275 3279
10. S. Giuriato, M. Foisseau, E. Dejean, D.W. Felsher, T. Al Saati, C. Demur, A. Ragab, A. Kruczynski, C. Schiff, G. Delsol, and F. Meggetto Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia Blood 115 2010 4061 4070
11. Q. Zhang, P.N. Raghunath, L. Xue, M. Majewski, D.F. Carpentieri, N. Odum, S. Morris, T. Skorski, and M.A. Wasik Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma J Immunol 168 2002 466 474
12. A. Zamo, R. Chiarle, R. Piva, J. Howes, Y. Fan, M. Chilosi, D.E. Levy, and G. Inghirami Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death Oncogene 21 2002 1038 1047
13. M. Marzec, M. Kasprzycka, X. Liu, M. El-Salem, K. Halasa, P.N. Raghunath, R. Bucki, P. Wlodarski, and M.A. Wasik Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway Oncogene 26 2007 5606 5614
14. M. Kasprzycka, M. Marzec, Z. Liu, Q. Zhang, and M.A. Wasik Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3 Proc Natl Acad Sci USA 103 2006 9964 9969
15. M. Marzec, Q. Zhang, A. Goradia, P.N. Raghunath, X. Liu, M. Paessler, H.Y. Wang, M. Wysocka, M. Cheng, B.A. Ruggeri, and M.A. Wasik Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) Proc Natl Acad Sci USA 105 2008 20852 20857
16. M. Cheng, M.R. Quail, D.E. Gingrich, G.R. Ott, L. Lu, W. Wan, M.S. Albom, T.S. Angeles, L.D. Aimone, F. Cristofani, R. Machiorlatti, C. Abele, M.A. Ator, B.D. Dorsey, G. Inghirami, and B.A. Ruggeri CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers Mol Cancer Ther 11 2012 670 679
17. F.Y. Hsu, P.B. Johnston, K.A. Burke, and Y. Zhao The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner Cancer Res 15 2006 9002 9008
18. G. Klein, E. Klein, and E. Kashuba Interaction of Epstein-Barr virus (EBV) with human B-lymphocytes Biochem Biophys Res Commun 396 2010 67 73
19. W.C. Hahn, C.M. Counter, A.S. Lundberg, R.L. Beijersbergen, M.W. Brooks, and R.A. Weinberg Creation of human tumour cells with defined genetic elements Nature 400 1999 464 468
20. B. Elenbaas, L. Spirio, F. Koerner, M.D. Fleming, D.B. Zimonjic, J.L. Donaher, N.C. Popescu, W.C. Hahn, and R.A. Weinberg Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells Genes Dev 15 2001 50 65
21. T.A. Ince, A.L. Richardson, G.W. Bell, M. Saitoh, S. Godar, A.E. Karnoub, J.D. Iglehart, and R.A. Weinberg Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes Cancer Cell 12 2007 160 170
22. N.P. Shah, and K. Shannon Advancing the STATus of MPN pathogenesis Blood 119 2012 3374 3376
23. R.S. Lee, C. Stewart, S.L. Carter, L. Ambrogio, K. Cibulskis, C. Sougnez, M.S. Lawrence, D. Auclair, J. Mora, T.R. Golub, J.A. Biegel, G. Getz, and C.W. Roberts A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers J Clin Invest 122 2012 2983 2988
24. L.C. Young, K.M. Bone, P. Wang, F. Wu, B.A. Adam, S. Hegazy, P. Gelebart, J. Holovati, L. Li, S.E. Andrew, and R. Lai Fusion tyrosine kinase NPM-ALK deregulates MSH2 and suppresses DNA mismatch repair function. Novel insights into a potent oncoprotein Am J Pathol 179 2011 411 421
25. H. Matsuyama, H.I. Suzuki, H. Nishimori, M. Noguchi, T. Yao, N. Komatsu, H. Mano, K. Sugimoto, and K. Miyazono miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma Blood 118 2011 6881 6892
26. C. Vicente-Dueñas, L. Fontán, I. Gonzalez-Herrero, I. Romero-Camarero, V. Segura, M.A. Aznar, E. Alonso-Escudero, E. Campos-Sanchez, L. Ruiz-Roca, M. Barajas-Diego, A. Sagardoy, J.I. Martinez-Ferrandis, F. Abollo-Jimenez, C. Bertolo, I. Peñuelas, F.J. Garcia-Criado, M.B. García-Cenador, T. Tousseyn, X. Agirre, F. Prosper, F. Garcia-Bragado, E.D. McPhail, I.S. Lossos, M.Q. Du, T. Flores, J.M. Hernandez-Rivas, M. Gonzalez, A. Salar, B. Bellosillo, E. Conde, R. Siebert, X. Sagaert, C. Cobaleda, I. Sanchez-Garcia, and J.A. Martinez-Climent Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice Proc Natl Acad Sci USA 109 2012 10534 10539
27. S. Newrzela, N. Al-Ghaili, T. Heinrich, M. Petkova, S. Hartmann, B. Rengstl, A. Kumar, H.M. Jäck, S. Gerdes, I. Roeder, M.L. Hansmann, and D. von Laer T-cell receptor diversity prevents T-cell lymphoma development Leukemia 12 2012 2499 2507
28. E.L. Kwak, Y.J. Bang, D.R. Camidge, A.T. Shaw, B. Solomon, R.G. Maki, S.H. Ou, B.J. Dezube, P.A. Jänne, D.B. Costa, M. Varella-Garcia, W.H. Kim, T.J. Lynch, P. Fidias, H. Stubbs, J.A. Engelman, L.V. Sequist, W. Tan, L. Gandhi, M. Mino-Kenudson, G.C. Wei, S.M. Shreeve, M.J. Ratain, J. Settleman, J.G. Christensen, D.A. Haber, K. Wilner, R. Salgia, G.I. Shapiro, J.W. Clark, and A.J. Iafrate Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? [Erratum appeared in N Engl J Med 2011, 364:588] N Engl J Med 363 2010 1693 1703
29. C. Gambacorti-Passerini, C. Messa, and E.M. Pogliani Crizotinib in anaplastic large-cell lymphoma N Engl J Med 364 2011 775 776